We are live on ! Find out more
EVFM

Evofem Biosciences, Inc. Common Stock
EVFM

Delisted

EVFM was delisted on the 10th of August, 2022.

Back to rankings

103 hedge funds and large institutions have $74.5M invested in Evofem Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

11% more funds holding

Funds holding: 93 → 103 (+10)

7% less capital invested

Capital invested by funds: $80M → $74.5M (-$5.48M)

14% less call options, than puts

Call options by funds: $1.05M | Put options by funds: $1.22M

Holders
103
Holders Change
+10
Holders Change %
+10.75%
% of All Funds
1.81%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
31
Increased
31
Reduced
19
Closed
18
Calls
$1.05M
Puts
$1.22M
Net Calls
-$167K
Net Calls Change
-$676K

Top Buyers

Rank Fund Capital Flow
1
MS
Maven Securities
Jersey
+$8.33M
2
CCM
CAAS Capital Management
New York
+$7.08M
3
BBA
Baker Bros. Advisors
New York
+$6.93M
4
GLA
Great Lakes Advisors
Illinois
+$5.14M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.72M

Top Sellers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
-$10.3M
2
Verition Fund Management
Verition Fund Management
Connecticut
-$362K
3
Squarepoint
Squarepoint
New York
-$239K
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$232K
5
AC
Aristides Capital
Kentucky
-$222K
Name Holding Trade Value Shares
Change 		Change in
Stake
TAM
26
Tocqueville Asset Management
New York
$387K -$195K -4,280 -23%
Charles Schwab
27
Charles Schwab
California
$344K -$20.6K -454 -3%
VF
28
Virtu Financial
New York
$305K +$496K +10,921 +1,540%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$273K – – –
FWSM
30
First Wilshire Securities Management
California
$263K +$455K +10,000 New
JP Morgan Chase
31
JP Morgan Chase
New York
$259K -$194K -4,270 -30%
Morgan Stanley
32
Morgan Stanley
New York
$231K +$91.3K +2,008 +30%
AllianceBernstein
33
AllianceBernstein
Tennessee
$208K – – –
California State Teachers Retirement System (CalSTRS)
34
California State Teachers Retirement System (CalSTRS)
California
$203K – – –
Barclays
35
Barclays
United Kingdom
$166K +$119K +2,624 +72%
CSS
36
Cubist Systematic Strategies
Connecticut
$141K +$245K +5,385 New
Citigroup
37
Citigroup
New York
$137K +$194K +4,262 +438%
RhumbLine Advisers
38
RhumbLine Advisers
Massachusetts
$134K +$2.32K +51 +1%
RC
39
RBF Capital
California
$122K – – –
Osaic Holdings
40
Osaic Holdings
Arizona
$116K +$71.3K +1,569 +56%
Deutsche Bank
41
Deutsche Bank
Germany
$92K -$14.1K -311 -8%
New York State Common Retirement Fund
42
New York State Common Retirement Fund
New York
$90K +$25.8K +567 +20%
CC
43
Callan Capital
California
$88K – – –
Manulife (Manufacturers Life Insurance)
44
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$86K -$6.18K -136 -4%
Commonwealth Equity Services
45
Commonwealth Equity Services
Massachusetts
$65K -$75K -1,650 -40%
VOYA Investment Management
46
VOYA Investment Management
Georgia
$61K – – –
Principal Financial Group
47
Principal Financial Group
Iowa
$60K -$3.82K -84 -4%
PPA
48
Parametric Portfolio Associates
Washington
$60K +$49.1K +1,081 +89%
AQR Capital Management
49
AQR Capital Management
Connecticut
$56K – – –
Citadel Advisors
50
Citadel Advisors
Florida
$54K +$93.2K +2,050 New
1
2
3 4 5

EVFM Hedge Fund Activity: Q1 2021 in Review

103 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2021, worth a combined $74.5M — down 6.8% from $80M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new EVFM positions and 18 closed out — a net gain of 13 holders — while 31 added to existing stakes and 19 trimmed.

The largest buyer was Maven Securities, opening a new position worth an estimated $8.33M. The largest seller was Invesco, cutting an estimated $10.3M.

  • 103 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2021, up from 93 in Q4 2020.
  • Funds reported $74.5M of Evofem Biosciences, Inc. Common Stock stock for Q1 2021, down 6.8% quarter-over-quarter.
  • 31 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2021 and 18 closed out, a net change of +13 holders.
  • The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2021 was Maven Securities, an estimated $8.33M added.
  • The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2021 was Invesco, an estimated $10.3M sold.

Based on aggregated 13F filings for Q1 2021.